Quarterly Report
Quarterly Report
Brisbane, April 19, 2018 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.

Anatara Lifesciences is pleased to advise a neutral cash flow for the quarter ending 31st March 2018 and an updated cash balance of $8.76 million as reported in the attached March Appendix 4C.

Anatara Chairman, Dr Mel Bridges said, "Since listing in October 2014, the Anatara team has worked diligently on delivering its key milestones, and is focused on continuing to do so. We are pleased to maintain a strong cash position and appreciate the patience of our shareholders whilst we positively move along the path to delivering shareholder value."

To view the full report, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.



General inquiries:
Dr Mel Bridges
Executive Chairman
Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 68) (Last 30 Days: 387) (Since Published: 2725) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (5354)

Research Report

Social Media